#1 Clinical Trials Search in Europe

Opevesostat Tosilate

Opevesostat Tosilate is an investigational drug currently being studied in clinical trials for the treatment of advanced prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). These trials aim to evaluate the safety, efficacy, and potential benefits of Opevesostat Tosilate compared to existing treatments for patients who have progressed on or after prior hormonal therapies and chemotherapy. The studies are exploring various combinations and treatment strategies to improve outcomes for patients with this challenging form of prostate cancer.

Table of Contents

What is Opevesostat Tosilate?

Opevesostat Tosilate, also known as MK-5684, is a new investigational drug being developed for the treatment of advanced prostate cancer[1]. It is currently being studied in clinical trials to evaluate its safety and effectiveness in patients with metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that has spread to other parts of the body and no longer responds to hormone therapy[2].

Medical Conditions Treated

Opevesostat Tosilate is primarily being investigated for the treatment of:

  • Metastatic castration-resistant prostate cancer (mCRPC): This is an advanced form of prostate cancer that has spread beyond the prostate gland to other parts of the body and continues to grow despite treatments that lower testosterone levels[3].

This condition occurs when prostate cancer evolves to resist standard hormone therapies, making it more challenging to treat.

How Opevesostat Works

While the exact mechanism of action of Opevesostat Tosilate is not fully described in the provided clinical trial information, it is being studied as a novel treatment approach for mCRPC. It is likely that Opevesostat works by targeting specific pathways involved in prostate cancer growth and progression that are different from or complementary to existing therapies[1].

Clinical Trials

Opevesostat Tosilate is currently being evaluated in several clinical trials:

  1. Phase 3 Trial (2023-504899-25-00): This study compares Opevesostat to alternative treatments (abiraterone acetate or enzalutamide) in patients with mCRPC who have previously been treated with hormonal therapy and chemotherapy[1].
  2. Phase 3 Trial (2023-504957-11-00): This study also compares Opevesostat to abiraterone acetate or enzalutamide, but in patients with mCRPC that progressed after treatment with one next-generation hormonal agent[2].
  3. Phase 1/2 Trial (2023-506288-33-00): This study evaluates the safety and efficacy of Opevesostat-based treatment combinations or Opevesostat alone in patients with mCRPC[3].

These trials aim to assess various aspects of Opevesostat’s performance, including:

  • Overall survival: How long patients live after starting treatment[1].
  • Radiographic progression-free survival: How long patients live without their cancer growing or spreading, as seen on imaging scans[1].
  • Objective response rate: The proportion of patients whose tumors shrink or disappear with treatment[2].
  • Time to pain progression: How long it takes for patients to experience worsening pain related to their cancer[2].
  • Prostate-specific antigen (PSA) response: Changes in PSA levels, which can indicate how well the treatment is working[3].

How Opevesostat is Administered

Opevesostat Tosilate is administered as a film-coated tablet taken orally[1]. The exact dosing regimen is still being determined through clinical trials. Patients in the trials may receive different doses to help researchers identify the most effective and safe dose for future use.

Potential Side Effects

As Opevesostat is still in clinical trials, the full range of potential side effects is not yet known. The trials are designed to carefully monitor and assess any adverse events that patients may experience. Some general side effects that are often associated with cancer treatments may include:

  • Fatigue
  • Nausea
  • Changes in appetite
  • Diarrhea or constipation

It’s important to note that the occurrence and severity of side effects can vary from person to person. Patients in clinical trials are closely monitored for any adverse events[3].

Patient Eligibility

Eligibility for treatment with Opevesostat Tosilate in clinical trials typically includes:

  • Confirmed diagnosis of metastatic castration-resistant prostate cancer[1]
  • Previous treatment with hormonal therapy and, in some cases, chemotherapy[1]
  • Evidence of disease progression despite previous treatments[2]
  • Adequate organ function[2]
  • No active central nervous system metastases[3]

Specific eligibility criteria may vary between different clinical trials and should be discussed with a healthcare provider.

Conclusion

Opevesostat Tosilate represents a promising new approach in the treatment of advanced prostate cancer, particularly for patients with metastatic castration-resistant prostate cancer. As clinical trials progress, more information will become available about its effectiveness, safety profile, and potential role in prostate cancer treatment. Patients interested in learning more about Opevesostat or participating in clinical trials should consult with their oncologist or healthcare provider.

Aspect Details
Drug Name Opevesostat Tosilate (MK-5684)
Condition Studied Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Trial Phases Phase 2 and Phase 3
Administration Oral (film-coated tablets)
Comparators Abiraterone acetate, Enzalutamide
Key Endpoints Overall Survival, Progression-Free Survival, PSA Response, Quality of Life
Patient Population Adults with mCRPC who progressed after hormonal therapy and/or chemotherapy
Safety Monitoring Adverse events, tolerability, organ function

FAQ

  • What is Opevesostat Tosilate? Opevesostat Tosilate is an investigational drug being studied for the treatment of advanced prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). It is being evaluated in clinical trials to determine its safety and effectiveness compared to existing treatments.
  • Who is eligible to participate in these clinical trials? Eligibility criteria vary between trials, but generally include adult men with confirmed metastatic castration-resistant prostate cancer who have progressed on or after prior hormonal therapies. Participants must have adequate organ function and meet specific health criteria. Detailed eligibility requirements are determined by each individual study.
  • What are the main objectives of these clinical trials? The main objectives of these trials are to evaluate the safety and efficacy of Opevesostat Tosilate compared to existing treatments like abiraterone acetate or enzalutamide. They aim to assess outcomes such as overall survival, progression-free survival, and quality of life in patients with mCRPC.
  • How is Opevesostat Tosilate administered? Opevesostat Tosilate is administered orally in the form of film-coated tablets. The specific dosing regimen and duration of treatment are being evaluated as part of the clinical trials.
  • What are some of the potential side effects being monitored in these trials? While specific side effects of Opevesostat Tosilate are still being studied, the trials are closely monitoring for any adverse events. General areas of focus include gastrointestinal effects, cardiovascular health, liver function, and overall tolerability. Participants are carefully monitored throughout the studies for any potential side effects or safety concerns.

Ongoing Clinical Trials on Opevesostat Tosilate

  • Study of ifinatamab deruxtecan alone or in combination with other treatments for patients with metastatic castration-resistant prostate cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Ireland Italy The Netherlands Poland +1

  • Study of MK-5684 compared to standard therapy in patients with breast cancer, ovarian cancer, or endometrial cancer

    Recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Opevesostat, Olaparib, and Cabazitaxel in Patients with Advanced Prostate Cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark Finland France Germany Ireland Italy +2

  • Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy and Chemotherapy

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Czechia Denmark Finland France Germany +8

  • Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy

    Recruiting

    3 1 1 1
    Investigated drugs:
    Czechia Estonia France Germany Greece Hungary +9

Glossary

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC): A form of advanced prostate cancer that has spread beyond the prostate to other parts of the body and continues to grow despite treatments that lower testosterone levels.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • Androgen Deprivation Therapy (ADT): A treatment that reduces levels of male hormones (androgens) to stop them from stimulating prostate cancer growth.
  • Prostate-Specific Antigen (PSA): A protein produced by the prostate gland. Elevated levels in the blood can indicate prostate cancer or other prostate conditions.
  • Next-Generation Hormonal Agent (NHA): Newer drugs designed to more effectively block the effects of androgens on prostate cancer cells.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Blinded Independent Central Review (BICR): A method of assessing treatment outcomes where independent experts review patient data without knowing which treatment the patient received.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Quality of Life (QoL): A measure of an individual's well-being and ability to carry out daily activities while dealing with a disease and its treatment.

References

  1. http://clinicaltrials.eu/trial/study-comparing-mk-5684-with-abiraterone-acetate-or-enzalutamide-for-patients-with-advanced-prostate-cancer-after-hormonal-therapy-and-chemotherapy/
  2. http://clinicaltrials.eu/trial/study-comparing-mk-5684-with-abiraterone-acetate-or-enzalutamide-for-patients-with-advanced-prostate-cancer-after-hormonal-therapy/
  3. http://clinicaltrials.eu/trial/study-of-opevesostat-olaparib-and-cabazitaxel-in-patients-with-advanced-prostate-cancer/